Bhagiradha Chemicals & Industries Ltd
BHAGCHEMBhagiradha Chemicals & Industries Ltd's earnings have outrun its stock. EPS grew +30.8% in a year against a −4.0% price move.
The sharpest disagreement: profits are rising, but only −14% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (14 weeks in) while the P/E sits at the 60th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +225.0% year on year, and −14% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Bhagiradha Chemicals & Industries Ltd trades at ₹257, in a confirmed uptrend and 14 weeks into that stage. That is −0.3% against its own 200-day average. It sits at 67% of a 52-week range of ₹180 to ₹296. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a confirmed uptrend — week 14 of stage 2, confirmed. At ₹257 it trades −0.3% versus its 200-day average and sits at 67% of its 52-week range (₹180–₹296).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +3,231% while the NIFTY 500 moved +273% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Bhagiradha Chemicals & Industries Ltd trades at 122.0× P/E, mid-range by its own standards (60th percentile). Its long-run median P/E is 79.0×, measured across 5.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 122.0× is mid-range by its own standards (60th percentile), against a long-run median of 79.0× measured over 5.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +30.8% against a −4.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +34.8%/yr price move, ~−4.6%/yr came from earnings growth and ~+39.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Bhagiradha Chemicals & Industries Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 4.7% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +21.8% | +2.2% | +11.0% | — |
| Profit | +28.6% | −26.3% | −4.8% | — |
| EPS | +30.8% | −31.4% | −9.2% | — |
| Share price | −4.0% | +26.7% | +34.8% | +33.2% |
4-Factor Sector Score
51.9/100 — rank 8 of 24 in Pesticides/Agrochemicals · 100% evidence confidence
Bhagiradha Chemicals & Industries Ltd scores 51.9 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 29.1 + 7 + 1.6 + 14.2 = 51.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Bhagiradha Chemicals & Industries Ltd reported ₹195 Cr of revenue in the Jun 26 quarter, +57.3% year on year. That is the 7th straight quarter of year-on-year growth. Over 6 years it has compounded at 13.9% a year. The last full year, FY26, came in at ₹536 Cr. The last four reported quarters add to ₹607 Cr.
FY26 revenue came in at ₹536 Cr (+21.8% on the year), capping 6 years at 13.9% compound. The latest quarter (Jun 26) printed ₹195 Cr, +57.3% year on year — the 7th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +32.8% growth against the decade's 13.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +33.7% over the last 4 quarters against +20.5%/yr over the last 8 — accelerating; TTM profit +133.3% vs +12.8%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Bhagiradha Chemicals & Industries Ltd's operating margin is 16.0% in the Jun 26 quarter, +9.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 7.0% to 16.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.0%, +9.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 7.0%–16.0%.
Why the margin moved: operating margin went +8.4 pp year on year while gross margin went +5.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Bhagiradha Chemicals & Industries Ltd earned ₹13.0 Cr of net profit in the Jun 26 quarter, +225.0% year on year. Full-year FY26 profit was ₹18.0 Cr. The 6-year compound rate is 17.0%. That is 6.7% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹13.0 Cr, +225.0% year on year. On the full year, FY26 printed ₹18.0 Cr (+28.6%), and the 6-year compound rate is 17.0%.
Why profit moved: revenue contributed +57.3% and the margin +9.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +90.0% vs revenue +32.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −14% of Bhagiradha Chemicals & Industries Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹12.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹163 Cr of capital spending, ₹−151 Cr was left as free cash.
FY26: operating cash of ₹12.0 Cr against reported profit of ₹18.0 Cr, leaving free cash of ₹−151 Cr after ₹163 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −14% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −14%: the cash cycle stretched 72 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 72 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Bhagiradha Chemicals & Industries Ltd's cash conversion cycle runs 148 days in FY26, up from 76 days in FY21. Capital spending ran ₹521 Cr over the last 3 years. At FY26 sales of ₹536 Cr each day of that cycle holds about ₹1.5 Cr, so roughly ₹217 Cr sits inside the business at any moment.
FY26: debtors at 139 days, inventory at 161 days — roughly 5.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 148 days, looser than FY21's 76.
The full loop: cash goes out to suppliers and production on day 0; stock waits 161 days to sell; customers pay about 139 days after that; and suppliers themselves are paid at 152 days — netting out to the 148-day cycle.
In money terms: at FY26 sales of ₹536 Cr, each day of the cycle holds about ₹1.5 Cr — so the 148-day loop keeps roughly ₹217 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹521 Cr over the last 3 fiscal years against ₹46.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹96.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Bhagiradha Chemicals & Industries Ltd earns a ROCE of 5% in FY26. Return on invested capital clears the cost of that capital by −7.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.4% net margin on 0.48× asset turns.
FY26 ROCE is 5%.
🚨 Why the return is what it is — the wiring (FY26): 3.4% net margin × 0.48× asset turns × 1.60× balance-sheet leverage ≈ 2.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 4.4% − 12.0% = a −7.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Bhagiradha Chemicals & Industries Ltd carries total debt of ₹234 Cr against shareholder equity of ₹698 Cr as of Mar 26, a debt-to-equity of 0.34. On the annual view that ratio went from 0.43 in FY22 to 0.34 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹234 Cr against shareholder equity of ₹698 Cr — a debt-to-equity of 0.34. On the annual view, debt-to-equity went from 0.43 (FY22) to 0.34 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Bhagiradha Chemicals & Industries Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved −0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −0.7 points over 8 quarters to 19.6%; Foreign institutions: −0.1 points over 8 quarters to 0.1%; Domestic institutions: −0.1 points over 8 quarters to 3.0%. Note the structure: promoters hold under 20% — this is a widely-held company where institutions, not a family, set the direction.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Bhagiradha Chemicals & Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bayer CropScience LtdBAYERCROP | 71.8/100Favorable setup94% evidence | BASING | 22.9/35 Revenue -2.8% · PAT 23.8% · OPM change 2 pp 100% evidence | 21.2/25 ROCE 29.1% · OPM 20% 100% evidence | 14.7/20 P/E 24.4× · PEG 1.28 100% evidence | 13.0/20 RS sector 9.4% · RS bench -11% · 1Y -21.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.9 + 21.2 + 14.7 + 13 = 71.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Titan Biotech Ltd524717 | 68.9/100Favorable setup82% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 2 pp 95% evidence | 20.1/25 ROCE 22.8% · OPM 21% 76% evidence | 5.7/20 P/E 53.3× · PEG — 50% evidence | 14.0/20 RS sector 35.7% · RS bench 34.4% · 1Y 213.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.1 + 5.7 + 14 = 68.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Sharda Cropchem LtdSHARDACROP | 64.7/100Mixed-positive evidence100% evidence | BASING | 24.2/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 100% evidence | 19.6/25 ROCE 30.2% · OPM 17% 100% evidence | 18.7/20 P/E 11× · PEG 0.26 100% evidence | 2.2/20 RS sector -14.6% · RS bench -15.4% · 1Y -16.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 19.6 + 18.7 + 2.2 = 64.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.6% and the one-year return is -16.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4Dharmaj Crop Guard LtdDHARMAJ | 63.2/100Mixed-positive evidence74% evidence | BASING | 21.1/35 Revenue 8.5% · PAT 13.2% · OPM change 1 pp 95% evidence | 15.9/25 ROCE 16.8% · OPM 15% 95% evidence | 10.9/20 P/E 15.1× · PEG — 15% evidence | 15.3/20 RS sector 5% · RS bench 4.5% · 1Y -27.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.1 + 15.9 + 10.9 + 15.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 60.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 23.4/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 17.9/25 ROCE 18.6% · OPM 12% 95% evidence | 11.6/20 P/E 19.5× · PEG — 50% evidence | 7.6/20 RS sector -6.2% · RS bench -5.8% · 1Y -4.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.4 + 17.9 + 11.6 + 7.6 = 60.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.9/100Mixed-positive evidence60% evidence | BREAKING OUT | 21.3/35 Revenue 48.4% · PAT 81.5% · OPM change 1 pp 95% evidence | 14.8/25 ROCE 19.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 21.3 + 14.8 + 10.8 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7India Pesticides LtdIPL | 52.9/100Mixed-positive evidence81% evidence | BASING | 20.1/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.7/25 ROCE 16.6% · OPM 14% 95% evidence | 14.1/20 P/E 14.3× · PEG — 50% evidence | 5.0/20 RS sector -11.9% · RS bench -17.5% · 1Y -35.3%1 of 11 weeks ahead 70% evidence |
| Exact sum: 20.1 + 13.7 + 14.1 + 5 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Bhagiradha Chemicals & Industries Ltdthis pageBHAGCHEM | 51.9/100Mixed-positive evidence100% evidence | ASLEEP | 29.1/35 Revenue 33.7% · PAT 100% · OPM change 9 pp 100% evidence | 7.0/25 ROCE 4.5% · OPM 16% 100% evidence | 1.6/20 P/E 122× · PEG 8.06 100% evidence | 14.2/20 RS sector 9.1% · RS bench 7.6% · 1Y -4.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 7 + 1.6 + 14.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Rallis India LtdRALLIS | 50.9/100Mixed-positive evidence94% evidence | BASING | 20.4/35 Revenue 4.4% · PAT 24.4% · OPM change 2 pp 100% evidence | 10.6/25 ROCE 14.1% · OPM 18% 100% evidence | 11.5/20 P/E 17.2× · PEG 2.15 100% evidence | 8.4/20 RS sector -1.8% · RS bench -19% · 1Y -43.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 10.6 + 11.5 + 8.4 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Astec Lifesciences LtdASTEC | 50.9/100Mixed-positive evidence69% evidence | BASING | 23.9/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 3.2/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.8/20 RS sector 5.1% · RS bench 3.6% · 1Y -17.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 3.2 + 10 + 13.8 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Jubilant Ingrevia LtdJUBLINGREA | 50.5/100Mixed-positive evidence93% evidence | TURNING | 19.0/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.4% · OPM 15% 100% evidence | 6.1/20 P/E 33× · PEG 2.41 65% evidence | 14.8/20 RS sector 0.7% · RS bench -0.6% · 1Y -8.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 10.6 + 6.1 + 14.8 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Sumitomo Chemical India LtdSUMICHEM | 46.2/100Mixed-negative evidence94% evidence | FADING | 12.6/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 5.5/20 P/E 41.6× · PEG 4 100% evidence | 9.1/20 RS sector -8.2% · RS bench 3.2% · 1Y -16.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 19 + 5.5 + 9.1 = 46.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13NACL Industries LtdNACLIND | 45.9/100Mixed-negative evidence100% evidence | ASLEEP | 29.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 3.9/25 ROCE 8.1% · OPM 11% 100% evidence | 3.7/20 P/E 142× · PEG 2.02 100% evidence | 9.2/20 RS sector -4.3% · RS bench -5.8% · 1Y -35%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 3.9 + 3.7 + 9.2 = 45.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Meghmani Organics LtdMOL | 45.8/100Mixed-negative evidence74% evidence | BREAKING OUT | 20.8/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 7.8/25 ROCE 6.7% · OPM 18% 95% evidence | 9.4/20 P/E 24.8× · PEG — 15% evidence | 7.8/20 RS sector -33.7% · RS bench 7.6% · 1Y -22%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.8 + 7.8 + 9.4 + 7.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Excel Industries LtdEXCELINDUS | 42.8/100Mixed-negative evidence74% evidence | TURNING | 12.4/35 Revenue 5.5% · PAT -20.4% · OPM change 0 pp 95% evidence | 10.3/25 ROCE 6.2% · OPM 14% 95% evidence | 10.4/20 P/E 17.3× · PEG — 15% evidence | 9.7/20 RS sector -4.6% · RS bench 1.7% · 1Y -15.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 10.3 + 10.4 + 9.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16UPL LtdUPL | 42.2/100Mixed-negative evidence91% evidence | BASING | 17.1/35 Revenue 12.9% · PAT 98.4% · OPM change -2 pp 74% evidence | 8.3/25 ROCE 10.1% · OPM 13% 100% evidence | 12.2/20 P/E 24.5× · PEG 0.5 100% evidence | 4.6/20 RS sector -11.6% · RS bench -12.5% · 1Y -16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.3 + 12.2 + 4.6 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Rasayan LtdBHARATRAS | 41.9/100Mixed-negative evidence87% evidence | ASLEEP | 10.8/35 Revenue -5.2% · PAT 3.6% · OPM change -3 pp 95% evidence | 13.6/25 ROCE 16% · OPM 15% 95% evidence | 14.4/20 P/E 13.2× · PEG — 50% evidence | 3.1/20 RS sector -32.8% · RS bench -34% · 1Y -53.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 13.6 + 14.4 + 3.1 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Epigral LtdEPIGRAL | 41.2/100Mixed-negative evidence94% evidence | TURNING | 7.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.5/25 ROCE 15.5% · OPM 25% 100% evidence | 14.4/20 P/E 18× · PEG 0.43 100% evidence | 4.8/20 RS sector -32.9% · RS bench -6.6% · 1Y -35.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 7.5 + 14.5 + 14.4 + 4.8 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Dhanuka Agritech LtdDHANUKA | 40.8/100Mixed-negative evidence100% evidence | BASING | 6.6/35 Revenue -5.6% · PAT -12.1% · OPM change -4 pp 100% evidence | 16.2/25 ROCE 23.8% · OPM 12% 100% evidence | 11.4/20 P/E 16.3× · PEG 1.72 100% evidence | 6.6/20 RS sector -11% · RS bench -12.4% · 1Y -38.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.6 + 16.2 + 11.4 + 6.6 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Best Agrolife LtdBESTAGRO | 40.0/100Mixed-negative evidence87% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.1/25 ROCE 5.2% · OPM 20% 95% evidence | 8.8/20 P/E 22.8× · PEG — 50% evidence | 14.2/20 RS sector -0.4% · RS bench -1.8% · 1Y -27.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 9.1 + 8.8 + 14.2 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Insecticides India LtdINSECTICID | 37.6/100Mixed-negative evidence87% evidence | BASING | 10.7/35 Revenue 1.3% · PAT -16.7% · OPM change -1 pp 95% evidence | 10.8/25 ROCE 15.8% · OPM 11% 95% evidence | 11.5/20 P/E 14.2× · PEG — 50% evidence | 4.6/20 RS sector -6.7% · RS bench -8% · 1Y -23.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.8 + 11.5 + 4.6 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22P I Industries LtdPIIND | 35.3/100Mixed-negative evidence94% evidence | BASING | 4.7/35 Revenue -16.6% · PAT -27.8% · OPM change -5 pp 100% evidence | 13.8/25 ROCE 15% · OPM 22% 100% evidence | 9.5/20 P/E 31.7× · PEG 1.71 100% evidence | 7.3/20 RS sector -3.4% · RS bench -25.1% · 1Y -38.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 4.7 + 13.8 + 9.5 + 7.3 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Heranba Industries LtdHERANBA | 28.0/100Adverse evidence77% evidence | BASING | 8.9/35 Revenue -2.6% · PAT -80% · OPM change 5.9 pp 95% evidence | 2.8/25 ROCE -1.7% · OPM 12.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.3/20 RS sector -19% · RS bench -20.3% · 1Y -48.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 2.8 + 10 + 6.3 = 28 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24GSP Crop Science LtdGSPCROP | 47.7/100Thin evidence · provisional38% evidence | BREAKING OUT | 14.2/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 13.6/25 ROCE 18.9% · OPM 11% 76% evidence | 9.9/20 P/E 21× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 9 weeks ahead 0% evidence |
| Exact sum: 14.2 + 13.6 + 9.9 + 10 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Bhagiradha Chemicals & Industries Ltd's share price today?
Bhagiradha Chemicals & Industries Ltd trades at ₹257, −4.0% over the past year. The company is valued at ₹3,355 Cr. The stock sits at 67% of its 52-week range of ₹180–₹296, −0.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 14 weeks in. — as of 11 September 2026.
What were Bhagiradha Chemicals & Industries Ltd's latest quarterly results?
Bhagiradha Chemicals & Industries Ltd reported revenue of ₹195 Cr and net profit of ₹13.0 Cr for the Jun 26 quarter. Revenue rose 57.3% and profit rose 225.0% year on year. Earnings per share were ₹1.03. The operating margin was 16.0%, 9.0 pp higher than a year earlier. — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's revenue?
Bhagiradha Chemicals & Industries Ltd reported revenue of ₹195 Cr in the Jun 26 quarter, +57.3% year on year. For the full FY26 fiscal year, revenue was ₹536 Cr (+21.8%). Over the last 6 years revenue compounded at 13.9% a year. — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's profit?
Bhagiradha Chemicals & Industries Ltd earned ₹13.0 Cr of net profit in the Jun 26 quarter, +225.0% year on year. Full-year FY26 profit was ₹18.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's market cap?
Bhagiradha Chemicals & Industries Ltd's market capitalisation is ₹3,355 Cr at a share price of ₹257. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's P/E ratio?
Bhagiradha Chemicals & Industries Ltd trades at a P/E of 122.0×, at the 60th percentile of its own 6-year range, against a long-run median of 79.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Bhagiradha Chemicals & Industries Ltd pay a dividend?
Yes — Bhagiradha Chemicals & Industries Ltd's dividend payout was 11% of profit in FY26, and it recorded a payout in 5 of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd overvalued?
On its own history, Bhagiradha Chemicals & Industries Ltd looks mid-range: its P/E of 122.0× sits at the 60th percentile of its 6-year range (long-run median 79.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd growing?
Yes — Bhagiradha Chemicals & Industries Ltd is growing: latest-quarter revenue +57.3% year on year, profit +225.0%, and the margin +9.0 pp at 16.0%. The 6-year compound rates are 13.9% (revenue) and 17.0% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Bhagiradha Chemicals & Industries Ltd performing?
Bhagiradha Chemicals & Industries Ltd is in a confirmed uptrend, 14 weeks in. Its latest quarter's revenue rose 57.3% and profit rose 225.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Bhagiradha Chemicals & Industries Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 4.7% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +33.7% latest, profit growth +133.3% latest, eps growth +118.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 14 of stage 2), trading −0.3% versus its 200-day average and at 67% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd beating the market?
Not lately — on a trailing-13-week view Bhagiradha Chemicals & Industries Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +3,231% against the NIFTY 500's +273% — ahead of the index over the full window. — as of 11 September 2026.
Will Bhagiradha Chemicals & Industries Ltd's share price go up?
This page publishes no price forecast for Bhagiradha Chemicals & Industries Ltd. What it measures instead: the share price is ₹257, the price is in a confirmed uptrend 14 weeks in. Its P/E of 122.0× sits at the 60th percentile of its own 6-year range. — as of 11 September 2026.
Who owns Bhagiradha Chemicals & Industries Ltd?
Promoters hold 19.6% of Bhagiradha Chemicals & Industries Ltd, foreign institutions 0.1%, domestic institutions 3.0% and the public 77.3% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Bhagiradha Chemicals & Industries Ltd have too much debt?
It is moderate — Bhagiradha Chemicals & Industries Ltd's debt-to-equity is 0.34, and operating profit covers the interest bill 3×. FY26 borrowings were ₹235 Cr against equity of ₹698 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's capex?
Bhagiradha Chemicals & Industries Ltd spent ₹521 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹163 Cr, with ₹96.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Bhagiradha Chemicals & Industries Ltd's cash flow?
Bhagiradha Chemicals & Industries Ltd generated ₹12.0 Cr of operating cash flow in FY26 and ₹−151 Cr of free cash flow after ₹163 Cr of capital spending. Reported profit that year was ₹18.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Bhagiradha Chemicals & Industries Ltd consumed cash while reporting profit. In FY26, operating cash was ₹12.0 Cr against reported profit of ₹18.0 Cr. Cash-flow resolution is annual — as of 11 September 2026.
Where is Bhagiradha Chemicals & Industries Ltd in its business cycle?
Bhagiradha Chemicals & Industries Ltd's FY26 operating margin was 11.0%, against a 7-year band of 7.0%–16.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Bhagiradha Chemicals & Industries Ltd story?
The sharpest disagreement: profits are rising, but only −14% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Bhagiradha Chemicals & Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Bhagiradha Chemicals & Industries Ltd's earnings have outrun its stock. EPS grew +30.8% in a year against a −4.0% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!